Switching all eligible patients to generic HIV drugs could save the U.S. $920 million in the first year the drugs are available, researchers at Massachusetts General Hospital report in the Annals of Internal Medicine, although they note that the brand-name single-pill combination drug is the best choice for first-line treatment for improved adherence and efficacy.

Related Summaries